Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This review discusses the effectiveness and tolerability of alpha1-adrenoceptor antagonists for managing lower urinary tract symptoms in benign prostatic hyperplasia, reporting no new clinical results.

This review discusses risk factors for intraoperative floppy iris syndrome, emphasizing tamsulosin and other α1 blockers, and underscores the importance of preoperative screening to mitigate surgical complications, but it reports no new results.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.

This study found that induced pluripotent stem cells derived from human keratinocytes efficiently differentiated into cardiomyocytes, forming a homogeneous population with cardiac-specific molecular and functional properties, and demonstrated significant cardiac marker expression and spontaneous contraction capabilities over 15 days of differentiation induction.

New treatments improved blood pressure control in patients with resistant hypertension.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This study suggests that targeting adenosine receptors could be an effective strategy for reducing inflammation in inflammatory skin disorders, with promising results observed in animal models.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This study found that minoxidil increased plasma renin activity in patients with hypertension through both an adrenergic mechanism related to heart rate changes and a secondary mechanism unrelated to propranolol.

In this study, researchers addressed the limitations of adenosine's practical application in treating inflammation, oxidative stress, and tissue repair due to its poor water solubility and low transdermal permeability. Results are not reported in the abstract.

Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.

This article discusses the use of direct vasodilators and sympatholytic agents in hypertension management, highlighting their utility in specific cases like refractory hypertension and heart failure, but reports no new clinical results.

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

This study found that neuroactive steroids like DHEA and pregnenolone influence cocaine-induced appetence in mice through their interaction with the ς₁ receptor, suggesting a role in individual vulnerability to addiction.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study found that most potassium channel blockers increased the activity of slowly adapting mechanoreceptors in rat whisker pads, while the opener NS1619 decreased their evoked activity.

This review discusses the uncommon but potentially serious cutaneous reactions to beta-adrenergic blockers and the uncertain pathogenesis, with no new clinical results reported.

This review discusses nonsteroidal selective androgen receptor modulators and their potential therapeutic applications but reports no new clinical findings.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

This study suggests that the 5α-reductase inhibitor finasteride modulates sensorimotor gating in rats by affecting D1 and D3 receptors, but not D2 receptors, with varying effects based on genetic strain.

This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.